Clinical trials: Myeloid Malignancy, open to volunteers
Relapsed Acute Myeloid Leukemia
Imetelstat Combinations in Relapsed AML
IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML.
- Trial name
- IMAGINE (NCT07320235)
- Testing
- Imetelstat, Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Douglas Tremblay
Acute Myeloid Leukemia, Adult
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
- Trial name
- NCT05133882
- Testing
- Clifutinib Besylate
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
AML, Adult
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
Mutations in IDH genes are found in numerous cancers and more specifically in acute myeloid leukemia (AML). These mutations target specific amino acids, at positions 140 or 172 of IDH2, and 132 of IDH1.
- Trial name
- NCT06377579
- Where
- 21 sites in France
- Volunteers
- 250 people
- Sponsor
- French Innovative Leukemia Organisation
Acute Myeloid Leukemia, Graft Versus Host Disease
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute…
- Conditions
- Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
- Trial name
- NCT06996119
- Testing
- Biospecimen Collection, Busulfan, Computed Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
This study evaluates the efficacy and safety of the combination of idarubicin and cytarabine induction followed by intermediate-dose cytarabine consolidation with venetoclax in the treatment of newly diagnosed adult acute myeloid…
- Trial name
- NCT06232694
- Testing
- Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;, Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;, utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid)
Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
A first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation…
- Conditions
- Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic
- Trial name
- ThINKK-01 (NCT07518654)
- Testing
- Therapeutic Inducers of Natural Killer Killing (ThINKK)
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Michel Duval
Acute Myeloid Leukemia (AML)
VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.
Objective: This clinical trial aims to compare the efficacy and safety of the VA-CAG regimen administered as a two-week schedule versus a three-week schedule for induction remission in acute myeloid leukemia (AML).
- Trial name
- NCT07642453
- Testing
- Venetoclax,Azacitidine,Arubicin,Cytarabine,G-CSF.
- Volunteers
- 110 people
- Sponsor
- Hematology department of the 920th hospital
Acute Myeloid Leukemia
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia…
- Trial name
- RIVER-81 (NCT06191263)
- Testing
- RVU120, Venetoclax
- Where
- 37 sites in France, Italy and 2 more
- Volunteers
- 98 people
- Sponsor
- Ryvu Therapeutics SA
Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML)
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML).
- Conditions
- Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
- Trial name
- CHANCE (NCT07172204)
- Testing
- Alternately treated with VA/low CHA regimen
- Where
- 5 sites in China
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort.
- Trial name
- NCT06529731
- Testing
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sawa Ito, MD
Acute Leukemia, Myelodysplastic Syndrome
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
- Trial name
- NCT07573111
- Testing
- QUAIL-100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Laguna Biotherapeutics, Inc.
Stem Cell Transplantation, Myelodysplastic Syndromes
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
The goal of this study is to test an electronic health (eHealth) mindfulness-based music therapy intervention to improve health-related quality of life and reduce symptom burden and disease activity in patients undergoing stem…
- Conditions
- Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT07469592
- Testing
- eHealth Mindfulness-based Music Therapy (eMBMT), eHealth Mindfulness Meditation (eMM)
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- University of Miami
Acute Myeloid Leukemia
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant
This is a Phase II pilot study to determine the efficacy of three fixed dose (1 x 108/kg) infusions of ex-vivo expanded human leukocyte antigen (HLA)-haploidentical donor natural killer (NK) cells (haploNK) in children and young…
- Trial name
- EXCEL (NCT04836390)
- Testing
- Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Michael Pulsipher
Acute Promyelocytic Leukemia (APL)
Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia
It is a non-randomized, multicenter, prospective study, aiming to treat patients with newly diagnosed acute promyelocytic leukemia with a combination of oral arsenic and atra, with low dose chemotherapy for those with high-risk…
- Trial name
- IC-APL2020 (NCT06982274)
- Testing
- Realgar-Indigo Naturalis Formulation
- Where
- Brazil
- Volunteers
- 115 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Chronic Myeloid Leukemia (CML)
Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network
The primary objective of the study is to assess the impact of the organizational model of the hematology center on the quality of life of patients with CML estimated through standardized tools (EORTC QLQ-30, CML24) and through…
- Trial name
- NCT07165535
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- University of Milano Bicocca
AML, Adult
MRD-positive AML Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the…
- Trial name
- NCT07131059
- Testing
- Ivosidenib, Gilteritinib, Venetoclax
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AML (Acute Myelogenous Leukemia)
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell…
- Trial name
- NCT06783790
- Testing
- Avapritinib, azacitidine, Venetoclax
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Myelodysplastic Syndromes, Myeloid Leukemia, Acute
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in…
- Trial name
- TMLI-MA (NCT06598969)
- Testing
- Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Acute Myeloid Leukemia
Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia
This is a prospective, multicenter, clinical-biological cohort study. Its objective is to assess the pharmacokinetics-pharmacodynamics (PK-PD) of venetoclax (VEN) in patients with Acute Myeloid Leukemia (AML).
- Trial name
- EUREKA-VEN (NCT07243483)
- Testing
- Pharmacokinetic dosages of venetoclax
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Leon Berard